Category Archives: Male Sexual Dysfunction

COLUMBIA, SC (WIS) - A Forest Acres couple is suing the state to challenge its decision to perform sexual-reassignment surgery on a toddler in its care who was born with both male and female internal sexual genitals. Mark and Pam Crawford, adoptive parents of the now 8-year-old child, spoke to the media Tuesday morning about the lawsuits filed in partnership with the Southern Poverty Law Center and other advocates in federal and state courts. The Crawfords say the child was born with intersex condition, which means a person is born with a sexual anatomy that doesn't fit the definition of a typical man or woman. The suit alleges the South Carolina Department of Social Services decided to perform "dangerous and mutilating surgery" in April, 2006. The decision to make the 16-month old a girl took away the child's right to choose his or her sexual identity later in life, the suit states. Named in the suit are the Department of Social Services, The Medical University of South Carolina, Greenville Health System and several other caregivers. "Doctors decided to play God," said a SPLC representative Tuesday morning in front of the federal courthouse. "It's too late for my son, but we … Continue reading →

The need for love and sexual intimacy does not decrease with age. Nevertheless, with ageing, the body undergoes certain changes that may have significant effects on sexual health. THE World Health Organization (WHO) has defined sexual health as the state of physical, mental and social well-being in relation to sexuality. It requires a positive and respectful approach to sexuality and sexual relationships, as well as the possibility of having pleasurable and safe sexual experiences, free of coercion, discrimination and violence. Sexual activity has its benefits. This includes improved mood by increasing endorphins in the body, which in turn will boost self esteem and prevent depression. It also strengthens the immune system, and coupled with the aerobic benefits, promotes longevity and enhances quality of life. Due to advances in science and medicine, the average lifespan of men and women have increased. With increasing age, there is a misconception that sex dies a natural death. This was dispelled by a study conducted by the National Council of Aging in the United States, where it was reported that 71% of men in their 60s and 57% of men in their 70s engaged in sexual activity at least once a month. The need for … Continue reading →

SAN DIEGO, 2013-05-10 14:30 CEST (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI) (http://www.apricusbio.com), today provided an update regarding ongoing corporate activities and announced that it expects to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission on Friday, May 10, 2013. As previously announced, the Company will host its first quarter 2013 financial results conference call today, May 10, 2013 at 9:00 a.m. ET. 'Apricus Bio began 2013 with a newly focused corporate strategy aimed at the commercialization, through partnerships, of its lead product Vitaros(r) for erectile dysfunction ('ED') and the development of its lead product candidate Femprox(r) for female sexual arousal disorder ('FSAD'),' said Richard Pascoe, Chief Executive Officer of Apricus Bio. 'Since the beginning of the year, we have made important progress in support of that goal, including the successful divestiture of multiple non-core assets, streamlining of our operations to better align them with our objectives, and advancement of our regulatory and commercial strategy for Vitaros(r) and Femprox(r). We continue to believe that the greatest opportunity for shareholder value creation remains in the global development and commercialization, through strategic partnerships, of these … Continue reading →

SAN DIEGO, May 10, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (APRI) (http://www.apricusbio.com), today provided an update regarding ongoing corporate activities and announced that it expects to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission on Friday, May 10, 2013. As previously announced, the Company will host its first quarter 2013 financial results conference call today, May 10, 2013 at 9:00 a.m. ET. "Apricus Bio began 2013 with a newly focused corporate strategy aimed at the commercialization, through partnerships, of its lead product Vitaros(R) for erectile dysfunction ("ED") and the development of its lead product candidate Femprox(R) for female sexual arousal disorder ("FSAD")," said Richard Pascoe, Chief Executive Officer of Apricus Bio. "Since the beginning of the year, we have made important progress in support of that goal, including the successful divestiture of multiple non-core assets, streamlining of our operations to better align them with our objectives, and advancement of our regulatory and commercial strategy for Vitaros(R) and Femprox(R). We continue to believe that the greatest opportunity for shareholder value creation remains in the global development and commercialization, through strategic partnerships, of these … Continue reading →

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (BPAX) today reported on its cash balance as of March 31, 2013 and financial results for the quarter ended March 31, 2013. As of March 31, 2013, the Companys cash and cash equivalents were approximately $29.4 million and convertible notes payable on May 1, 2013 were approximately $8.2 million. Subsequent to the end of the quarter and prior to the May 1, 2013 maturity date of the notes, the Company repaid the outstanding principal amount of the notes, plus all accrued and unpaid interest thereon. BioSante incurred a net loss of approximately $2.3 million or $(0.09) per share for the quarter ended March 31, 2013, compared to a net loss of $10.3 million or $(0.53) per share for the same period in 2012. The decrease in the net loss was due primarily to lower clinical development expenses for LibiGel (testosterone gel) during the most recent period as a result of the conclusion of all current LibiGel clinical studies. About BioSante Pharmaceuticals, Inc. BioSantes corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and its company, including licenses, business collaborations and other business combinations … Continue reading →

Treatments purporting to offer "male rejuvenation" and combat the effects of aging have become popular in recent years, but such claims are not backed up by science, experts say. Men seeking such treatments often receive testosterone, sometimes in combination with other hormones such as including steroids and growth hormones. Advertisers claim the treatments increase strength and sex drive, and make patients feel younger. However, studies examining the effects these treatments are lacking, and there's little evidence to support their use in men who don't have hormone deficiencies, experts say. "There's really no scientific evidence that they will help a man to function optimally, either in the sexual arena, or that they will have a effect on the general health and wellbeing of a man," said Dr. Eli Lizza, a urologist at Lenox Hill Hospital in New York. Moreover, the treatments also have side effects that should be considered. For instance, testosterone treatments can temporarily decrease sperm count and impair fertility, experts said. Further, studies have suggested a possible link between the receiving the hormone and prostate cancer. If you're looking for a way to lengthen lifespan and increase strength, some say you're better off sticking with the common sense advice … Continue reading →

Why Wait? Enlast Personal Male Lubricant. Stop Premature Ejaculation In Its Tracks With Enlast.flv http://mhlnk.com/C1BD0EF9 Click the link to order your Enlast to stop premature ejaculation, qualify for a FREE bottle Enlast offer and have it delivered str... By: truthwhiz … Continue reading →

LINCOLNSHIRE, Ill. & BAUDETTE, Minn.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (BPAX) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. announced today that each company will hold a special meeting of its stockholders on Wednesday, June 19, 2013 to consider and vote on certain matters in connection with the proposed merger of a subsidiary of BioSante into ANI pursuant to the amended and restated agreement and plan of merger dated April 12, 2013. BioSante and ANI have fixed the close of business on May 8, 2013 as the record date for the purpose of determining the stockholders who are entitled to notice of, and to vote at, their respective special meetings of stockholders. The special meeting of BioSante stockholders will be held at 8:00 a.m., Central Time, at BioSantes corporate office located at 111 Barclay Boulevard, Lincolnshire, Illinois 60069. The special meeting of ANIs stockholders will be held at 9:00 a.m., Eastern Time, at the offices of MVP Capital Partners located at 259 N. Radnor-Chester Road, Suite 130, Radnor, Pennsylvania 19087. BioSante and ANI stockholders are encouraged to read the definitive joint proxy statement/prospectus in its entirety as it provides, among other things, a detailed discussion of the proposed merger, the merger … Continue reading →

SAN DIEGO, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (APRI) (www.apricusbio.com) announced today that it will hold a conference call to discuss its first quarter 2013 financial results and recent corporate highlights on Friday, May 10, 2013 at 9:00 a.m. ET. The Company expects to file its Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission on Friday, May 10, 2013. The call can be accessed in the U.S. by dialing 877-407-9210 and outside of the U.S. by dialing 201-689-8049 and asking the conference operator for the Apricus Bio Conference Call. The conference call will also be webcast live at http://www.investorcalendar.com/IC/CEPage.asp?ID=170957. The teleconference replay will be available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay Passcode 413843 is required for playback. The webcast replay will be available for three months. About Apricus Biosciences, Inc. Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros(R), for the treatment of erectile … Continue reading →

Lightning Rod capsules are sold nationwide over the counter and via the Internet as a dietary supplement marketed for male sexual enhancement. Chang Kwung is conducting a voluntary recall after being notified by the US FDA that analytical testing found the Lightning Rod Capsules to contain an analogue of Sildenafil. Sildenafil is the active ingredient in an FDA-approved drug used for the treatment of male Erectile Dysfunction (ED), making Lightning Rod Capsules an unapproved new drug. The active drug ingredient is not listed on the label for this product. Use of this product may pose a threat to consumers because the analogue may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. ED is a common problem in men with these conditions, and consumers may seek these types of products to enhance sexual performance. To date, the firm has not received any reports of adverse events related to this recall or is aware of any illnesses associated with this product. Chang Kwung Inc. advises any customer in possession of Lightning Rod Capsules matching the description above, … Continue reading →